CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 15.6 HKD -1.27%
Market Cap: 9B HKD

Net Margin
CARsgen Therapeutics Holdings Ltd

-621%
Current
-2 346%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-621%
=
Net Income
-521.9m
/
Revenue
84m

Net Margin Across Competitors

No Stocks Found

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
9B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
11.12 HKD
Overvaluation 29%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-621%
=
Net Income
-521.9m
/
Revenue
84m
What is the Net Margin of CARsgen Therapeutics Holdings Ltd?

Based on CARsgen Therapeutics Holdings Ltd's most recent financial statements, the company has Net Margin of -621%.

Back to Top